IGF-1 Regulates Skeletal Muscle Degradation and Remolding in Ventilator-Induced Diaphragmatic Dysfunction by Mediating FOXO1 Expression
Luyu Yang,Xiaohong Jiang,Shouzhi Fu,Jinhui Tan,Wankang Dian,Yumei Zhou
DOI: https://doi.org/10.24976/discov.med.202436181.38
2024-01-01
Discovery medicine
Abstract:BACKGROUND: Mechanical ventilation (MV) sustains life in critically ill patients by providing adequate alveolar ventilation. However, prolonged MV could induce inspiratory muscle atrophy known as ventilator-induced diaphragmatic dysfunction (VIDD). Insulin-like growth factor (<i>IGF</i>)<i>-1</i> has been proven to play crucial roles in regulating skeletal muscle size and function. Meanwhile, the forkhead box protein O1 (<i>FOXO1</i>) has been linked to muscle atrophy. This study aimed to explore the effect of <i>IGF-1</i> on muscle degradation and remodeling in VIDD and delved into the association of the underlying mechanism involving <i>FOXO1</i>.METHODS: VIDD models were established by treating rats with MV. Adeno-associated virus (AAV) was used for transfection to construct <i>IGF-1</i> and/or <i>FOXO1</i> overexpressed rats. There were four groups in this study: normal rats (NC), normal rats with MV treatment (MV), <i>IGF-1</i>-overexpressed rats with MV treatment (MV+<i>IGF-1</i>), and rats overexpressing both <i>IGF-1</i> and <i>FOXO1</i> with MV treatment (MV+<i>IGF-1</i>+<i>FOXO1</i>). Protein levels were measured by western blot or enzyme-linked immunosorbent assay (ELISA), and mRNA levels were detected by real-time reverse transcriptase-polymerase chain reaction (RT-qPCR). <i>IGF-1</i> and <i>FOXO1</i> expression were validated by detecting mRNA and protein levels. Diaphragmatic muscle contractility and morphometry were tested using stimulating electrodes in conjunction with hematoxylin and eosin (H&E) staining. Interleukin (IL)-6 and carbonylated protein were used for evaluating muscle atrophy and oxidation, respectively. Protein degradation was determined by troponin-I level and tyrosine release. Apoptosis was assessed using the terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate (UTP) nick-end labeling (TUNEL) assay, alongside markers like Bax, B-cell lymphoma 2 (BCL-2), and Cleaved Caspase-3. Atrogin-1, muscle RING finger 1 (<i>MURF1</i>), neuronally expressed developmentally downregulated 4 (<i>NEDD4</i>), muscle ubiquitin ligase of SCF complex in atrophy-1 (<i>MUSA1</i>), and ubiquitinated protein was used to determine proteolysis. Additionally, protein synthesis was measured by assessing the rates of mixed muscle protein (MMP) and myosin heavy chain (MHC).RESULTS: MV treatment caused <i>IGF-1</i> downregulation (<i>p</i> < 0.01) and <i>FOXO1</i> upregulation (<i>p</i> < 0.01). The <i>IGF-1</i> upregulation downregulated <i>FOXO1</i> in the MV+<i>IGF-1</i> group (<i>p</i> < 0.001) while <i>IGF-1</i> and <i>FOXO1</i> were both upregulated in the MV+<i>IGF-1</i>+FOXO1 group (<i>p</i> < 0.001). The treatment of MV decreased muscle contractility and cross-sectional areas of diaphragm muscle fibers (<i>p</i> < 0.01). Additionally, IL-6, troponin-1, tyrosine release, carbonylated protein, TUNEL positive nuclei, Bax, Cleaved Caspase-3, Atrogin-1, <i>MURF1</i>, neuronally expressed developmentally downregulated 4 (<i>NEDD4</i>), <i>MUSA1</i>, and ubiquitinated protein levels increased significantly in MV group (<i>p</i> < 0.001) while levels of BCL-2, fractional synthetic rate of MMP and MHC, and type I and type II MHC protein mRNA expression decreased in MV group (<i>p</i> < 0.001). All of these alterations were reversed in the MV+<i>IGF-1</i> group (<i>p</i> < 0.01), while the <i>IGF-1</i>-induced reversion was disrupted in the MV+<i>IGF-1</i>+<i>FOXO1</i> group (<i>p</i> < 0.01).CONCLUSIONS: <i>IGF-1</i> may protect diaphragmatic muscles from VIDD-induced structural damage and function loss by downregulating <i>FOXO1</i>. This action suppresses muscle breakdown and facilitates muscle remodeling in diaphragmatic muscles affected by VIDD.
medicine, research & experimental